Core Insights - Sona Nanotech Inc has received ethics committee approval for a pilot cancer study, marking a significant step in its clinical development pathway focused on late-stage melanoma patients [1][4][8] - The current early feasibility study involves 10 patients with late-stage melanoma who have not responded to other treatments, with results expected within the current quarter [2][6] - The upcoming pilot study will expand to 30 to 40 patients, aiming to assess safety and efficacy after operational adjustments from the initial study [7][8] Company Developments - The company is currently conducting its first human trial, which is essential for understanding the medical device's functionality in a clinical setting [5][6] - The timeline for transitioning to the pilot study is contingent on obtaining regulatory approval, with hopes to initiate by late this year or early next year [8][9] - The company is focused on efficiently moving from one study to the next, demonstrating a proactive approach in its clinical development strategy [9]